obesity-995x60.png
FEATURED ARTICLES
The "Hidden" Reasons Psychiatric Drug Programs Fail After Phase I
Phase I success doesn’t eliminate development risk. Test critical assumptions around dose, biomarkers, target engagement, and patient biology before advancing.
-
What Happens When Acquisition Due Diligence Ignores Clinical Operations?
An acquisition’s hidden costs can emerge at clinical trial sites. Here’s why leadership needs to consider clinical operations in due diligence.
-
A Calculated Move: Putting Environmental Assessment Data To Wider Use
See how stronger data, cross-functional expertise, and earlier lifecycle analysis can help teams compare design choices, evaluate trade-offs, and identify opportunities to reduce environmental impact.
-
Who's Wearing The Patient Recruitment Hat When Your Trial Decisions Are Made?
Recruitment problems can start long before actual recruitment. Who is making sure your team gets ahead of those challenges?